Amorepacific publishes an SCI-grade analysis paper on blue gentle
Amorepacific has published an SCI-quality research paper on the harmfulness of blue light and a clinical evaluation method for blocking blue light and its effectiveness
The Anti-Pollution Research Center of Cupid Pacific The R&D center developed the world's first clinical evaluation method that prevents blue light from reaching the skin. The research paper, which includes studying the harmful effects of blue light on the skin, developing clinical devices, reviewing the effectiveness of blocking agents, etc., was published in the August 18, 2020 (19th edition of 2020) edition of the Journal of Cosmetic Dermatology, the SCI-class international academic journal.
Blue light is part of the blue wavelength of the visible light spectrum in the range from 380 to 500 nm (nanometers). Blue light has the shortest wavelength and strongest energy among all types of visible light, and prolonged exposure to this type of light is known to have detrimental effects, such as sleep disturbance and visual impairment.
Blue light can also have detrimental effects on the skin, including skin pigmentation and a reduction in skin elasticity and moisture. However, prior to research by Amorepacific, a popular Korean cosmetic brand, there was no clinical research that specifically demonstrated the harmfulness of everyday skin exposure to blue light.
Cho Hong-ri, a senior researcher at the Anti-Pollution Research Center at the Amorepacific R&D Center, has developed a device that can detect skin-damaging blue light wavelengths and clinically evaluate the blue light blocking performance at those wavelengths.
The new device developed by Amorepacific generates wavelengths of blue light that modern people are often exposed to from artificial light from smartphones, televisions, etc. Also, by fine-tuning the intensity and timing of the light, the device makes it easy to guide clinical assessments of skin damage that people may suffer in their daily lives from exposure to blue light.
Through an experiment with the clinical device, the Amorepacific R&D Center showed that blue light with a wavelength of 456 nm causes skin pigmentation. Based on the findings, Amorepacific tested whether a blue light blocker developed and released by the company could actually prevent skin pigmentation, with the company then demonstrating the blue light blocking effect of the blocker by measuring changes in the melanin index values. Etc.
The Amorepacific R&D Center has been investigating the harmfulness of blue light on the skin since 2017. In particular, the results of the company's research on its own clinical assessment method for blue light blocking performance, which is the first of its kind in the world, were presented at the IFSCC (International Association of Cosmetic Chemists) conference held in Munich in 2018.
In the future, Amorepacific plans to conduct further research on the effects on the environment and the resulting skin changes, and to further develop products to protect the skin health of customers around the world.
